Investors are always looking for stocks that are poised to beat at earnings season and GlaxoSmithKline plc GSK may be one such company. The firm has earnings coming up pretty soon, and events are ...

GlaxoSmithKline plc GSK, one of the largest health care companies, reshaped its business following the March 2015 completion of the three-part, inter-conditional transaction with Novartis related ...

GlaxoSmithKline plc (NYSE:GSK) Q1 2020 Results Conference Call April 29, ... and I'm pleased to report that our Company is performing well and has demonstrated resilience in the face of ...

In EvaluatePharma's report, Novartis--expected to land in 5th place by 2020--is the sole company in the top 10 expected to see negative growth, falling from 2014's sales of $1.53 billion to 2020 ...

GlaxoSmithKline and Sanofi announced positive results Monday from mid-stage testing of their experimental Covid-19 vaccine, which they hope to have in the market by the end of the year.

The report said GSK’s former head of vaccine development, Philip Dormitzer, who joined the company after working at rival Pfizer, had told his GSK colleagues about the delay.

Sanofi and GlaxoSmithKline said that their experimental COVID-19 vaccine succeeded in a mid-stage trial. The pharma giants plan to launch a pivotal-stage study with 35,000 volunteers in the coming ...

By Ben Hirschler LONDON (Reuters) - GlaxoSmithKline could file up to 20 new drugs for regulatory approval before 2020 as it seeks to revitalize a portfolio hit by falling sales of best-selling ...

GlaxoSmithKline PLC (NYSE:GSK) Q2 2020 Earnings Conference Call July 29, 2020 9:00 AM ETCompany ParticipantsSarah Elton-Farr - Head, IREmma Walmsley - CEO ...

GlaxoSmithKline could file up to 20 new drugs for regulatory approval before 2020 as it seeks to revitalize a portfolio hit by falling sales of best-selling inhaled lung treatment Advair, the ...